A Phase 2, Double Blind, Up to 40 Week, Multicenter Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis (EE) and Maintenance of Healed EE in Pediatric Subjects Aged 1 to 11 Years With EE

Trial Profile

A Phase 2, Double Blind, Up to 40 Week, Multicenter Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis (EE) and Maintenance of Healed EE in Pediatric Subjects Aged 1 to 11 Years With EE

Suspended
Phase of Trial: Phase II

Latest Information Update: 21 Jul 2016

At a glance

  • Drugs Dexlansoprazole (Primary)
  • Indications Erosive oesophagitis
  • Focus Therapeutic Use
  • Sponsors Takeda
  • Most Recent Events

    • 10 Mar 2016 Status changed from not yet recruiting to suspended, according to ClinicalTrials.gov record.
    • 02 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top